Verastem SEC Filings

Verastem, Inc. filed a current report describing two related communications to the market. The company issued a press release with preliminary financial results for the quarter and full fiscal year ended December 31, 2025. These preliminary figures give an early view of Verastem’s recent operating performance.

In the same press release, Verastem also outlined its key strategic priorities for 2026, providing an overview of management’s focus areas for the coming year. The press release is furnished as an exhibit to the report, which is signed by Chief Executive Officer Daniel W. Paterson.

Verastem, Inc. Chief Financial Officer receives equity grant in the form of 16,665 shares of Common Stock on January 21, 2026, reported at a price of $0.00 per share as an award, not an open-market purchase. These shares arise from restricted stock units (RSUs) granted under Verastem's Amended and Restated 2021 Equity Incentive Plan, with each RSU representing the right to receive one share of Common Stock.

The RSUs vest in three equal annual installments of approximately 33.3% on each of the first three anniversaries of January 21, 2026, becoming fully vested on January 21, 2029, as long as the CFO continues to serve as an employee or other service provider on each vesting date. Following this grant, the CFO directly beneficially owns 121,384 shares of Verastem common stock.

Verastem, Inc. reported an equity award to its President and CEO, Dan Paterson. On January 21, 2026, he was granted 213,785 shares of Verastem common stock in the form of restricted stock units (RSUs) at a price of $0.00 per share under the company’s Amended and Restated 2021 Equity Incentive Plan. Following this grant, he beneficially owns 613,889 shares of common stock directly.

The RSUs are scheduled to vest over three years. They vest as to 33.3% of the award on each of the first three anniversaries of January 21, 2026, so that the grant is fully vested on January 21, 2029. Vesting requires that Paterson continue to serve as an employee or other service provider to Verastem on each vesting date.

Verastem, Inc. (VSTM) insider Daniel Calkins has filed notice of a planned stock sale under Rule 144. The filing covers up to 5,039 shares of Verastem common stock to be sold through Shareworks by Morgan Stanley on or about 01/12/2026 on the NASDAQ, with an aggregate market value of $36,069.00. The filing notes that 66,776,006 shares of Verastem common stock were outstanding.

The 5,039 shares to be sold were acquired on 01/10/2025 through the vesting of a restricted stock unit award from Verastem, Inc. For additional context, during the past three months Daniel Calkins sold 80 Verastem shares on 12/24/2025 for gross proceeds of $628.80.

Verastem, Inc. insider Daniel Paterson has filed a Form 144 to sell 10,321 shares of Verastem common stock. The planned sale has an aggregate market value of $73,851.00 based on the figures provided, with the shares to be sold through Shareworks by Morgan Stanley on the NASDAQ, with an approximate sale date of 01/12/2026. Verastem had 66,776,006 common shares outstanding according to the notice.

The 10,321 shares proposed for sale were acquired on 01/10/2025 through the vesting of a restricted stock unit award from Verastem, with the same date listed as the payment date and the consideration described as N/A. The filing also lists multiple prior sales of Verastem securities by Daniel Paterson over the past three months, including 3,299 shares sold on 11/03/2025 for $32,146.00 and 2,000 shares sold on 12/11/2025 for $20,000.00.

Verastem, Inc. reported an insider share sale by its President and CEO, Dan Paterson. On January 12, 2026, he sold 10,321 shares of Verastem common stock at a price of $7.16 per share.

According to the disclosure, this sale was made to satisfy statutory tax withholding requirements tied to the vesting of restricted stock units, meaning it was connected to equity compensation rather than an open-market discretionary sale. After this transaction, Paterson beneficially owned 400,104 shares of Verastem common stock directly.

Verastem, Inc. Chief Financial Officer Form 4 filing reports a small, routine sale of company stock tied to equity compensation. On January 12, 2026, the CFO, Daniel Calkins, sold 5,039 shares of Verastem common stock at $7.16 per share. According to the footnote, this sale was made to satisfy statutory withholding tax requirements in connection with the vesting of restricted stock units, rather than as a discretionary sale of shares.

Following this transaction, the reporting person beneficially owned 104,719 shares of Verastem common stock, held directly. The filing is made by a single reporting person in the capacity of Chief Financial Officer and reflects standard administration of equity awards.

Verastem, Inc. filed a current report to inform investors that it has posted an updated corporate presentation on its website. The updated presentation, dated January 8, 2026, is also included as Exhibit 99.1.

This type of disclosure is meant to provide the market with the same information that the company is sharing in its investor materials, helping ensure all investors have equal access to the updated corporate overview and strategy details.

Verastem, Inc. reported an insider equity award for Michael Kauffman, who serves as both a director and President of Development. On January 6, 2026, he received a stock option covering 200,000 shares of Verastem common stock with an exercise price of $6.88 per share, held directly.

The option vests over three years: 33.33% of the shares vest on the first anniversary of the January 6, 2026 grant date, and an additional 8.33% vest at the end of each three‑month period thereafter until the third anniversary. Vesting requires that Kauffman continue to serve as an employee or other service provider to Verastem on each vesting date.